Literature DB >> 19667236

Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis.

Giuseppe Danilo Norata1, Patrizia Marchesi, Vivek Krishna Pulakazhi Venu, Fabio Pasqualini, Achille Anselmo, Federica Moalli, Irene Pizzitola, Cecilia Garlanda, Alberto Mantovani, Alberico Luigi Catapano.   

Abstract

BACKGROUND: Immune responses participate in several phases of atherosclerosis; there is, in fact, increasing evidence that both adaptive immunity and innate immunity tightly regulate atherogenesis. Pentraxins are a superfamily of acute-phase proteins that includes short pentraxins such as C-reactive protein or long pentraxins such as PTX3, a molecule acting as the humoral arm of innate immunity. To address the potential role of PTX3 in atherogenesis, we first investigated the expression of PTX3 during atherogenesis, generated double-knockout mice lacking PTX3 and apolipoprotein E, and then studied the effect of murine PTX3 deficiency on plasma lipids, atherosclerosis development, and gene expression pattern in the vascular wall. METHODS AND
RESULTS: PTX3 expression increases in the vascular wall of apolipoprotein E-knockout mice from 3 up to 18 months of age. Double-knockout mice lacking PTX3 and apolipoprotein E were fed an atherogenic diet for 16 weeks. Aortic lesions were significantly increased in double-knockout mice and mice heterozygous for PTX3 compared with apolipoprotein E-knockout mice. Mice lacking PTX3 showed a more pronounced inflammatory profile in the vascular wall as detected by cDNA microarray and quantitative polymerase chain reaction analysis and an increased macrophage accumulation within the plaque. Finally, lesion size correlated with the number of bone marrow monocytes.
CONCLUSIONS: PTX3 has atheroprotective effects in mice, which, in light of the cardioprotective effects recently reported, suggests a cardiovascular protective function of the long pentraxin 3 through the modulation of the immunoinflammatory balance in the cardiovascular system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19667236     DOI: 10.1161/CIRCULATIONAHA.108.806547

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  108 in total

1.  Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.

Authors:  Tiziano Barbui; Alessandra Carobbio; Guido Finazzi; Alessandro M Vannucchi; Giovanni Barosi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro Pancrazzi; Silvia Salmoiraghi; Pio Zilio; Cosimo Ottomano; Roberto Marchioli; Ivan Cuccovillo; Barbara Bottazzi; Alberto Mantovani; Alessandro Rambaldi
Journal:  Haematologica       Date:  2010-12-20       Impact factor: 9.941

2.  Racial differences in the association of pentraxin-3 with kidney dysfunction: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Ruth Dubin; Michael Shlipak; Yongmei Li; Joachim Ix; Ian H de Boer; Nancy Jenny; Carmen A Peralta
Journal:  Nephrol Dial Transplant       Date:  2010-11-15       Impact factor: 5.992

3.  Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study.

Authors:  Ruth Dubin; Yongmei Li; Joachim H Ix; Michael G Shlipak; Mary Whooley; Carmen A Peralta
Journal:  Am Heart J       Date:  2012-02       Impact factor: 4.749

4.  Pathophysiology of thrombosis in myeloproliferative neoplasms.

Authors:  Raffaele Landolfi; Leonardo Di Gennaro
Journal:  Haematologica       Date:  2011-02       Impact factor: 9.941

5.  Pentraxin 3: A Biomarker Link between Inflammation and Cardiovascular Risk among Obese Children.

Authors:  Yan-Ting Chen; Hui-Hsuan Wang; Ping-Yen Liu
Journal:  Acta Cardiol Sin       Date:  2021-03       Impact factor: 2.672

6.  Exercise reduced pentraxin 3 levels produced by endotoxin-stimulated human peripheral blood mononuclear cells in obese individuals.

Authors:  Aaron L Slusher; Yoshimi Shibata; Michael Whitehurst; Arun Maharaj; Justin M Quiles; Chun-Jung Huang
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-25

7.  Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.

Authors:  Mahmut Ilker Yilmaz; Juan Jesús Carrero; Jose Luis Martín-Ventura; Alper Sonmez; Mutlu Saglam; Turgay Celik; Halil Yaman; Mujdat Yenicesu; Tayfun Eyileten; Juan Antonio Moreno; Jesús Egido; Luis Miguel Blanco-Colio
Journal:  Clin J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 8.237

8.  Relationship between Plasma Pentraxin-3, Neutrophil-to-Lymphocyte Ratio, and Atherosclerosis in Renal Transplant Patients.

Authors:  Kultigin Turkmen; Fatih Mehmet Erdur; Ibrahim Guney; Huseyin Ozbiner; Aysun Toker; Abduzhappar Gaipov; Orhan Ozbek; Mehdi Yeksan; Halil Zeki Tonbul; Suleyman Turk
Journal:  Cardiorenal Med       Date:  2012-11-16       Impact factor: 2.041

9.  Aerobic fitness alters the capacity of mononuclear cells to produce pentraxin 3 following maximal exercise.

Authors:  Aaron L Slusher; Tiffany M Zúñiga; Edmund O Acevedo
Journal:  Eur J Appl Physiol       Date:  2018-05-10       Impact factor: 3.078

Review 10.  Biology of human pentraxin 3 (PTX3) in acute and chronic kidney disease.

Authors:  Marijn M Speeckaert; Reinhart Speeckaert; Juan J Carrero; Raymond Vanholder; Joris R Delanghe
Journal:  J Clin Immunol       Date:  2013-02-27       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.